Search Results - "Bideault, F."

Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations by Langrand-Escure, J., de Crevoisier, R., Llagostera, C., Créhange, G., Delaroche, G., Lafond, C., Bonin, C., Bideault, F., Sargos, P., Belhomme, S., Pasquier, D., Latorzeff, I., Supiot, S., Hennequin, C.

“…Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk…”
Get full text

Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations by Langrand-Escure, J., de Crevoisier, R., Llagostera, C., Créhange, G., Delaroche, G., Lafond, C., Bonin, C., Bideault, F., Sargos, P., Belhomme, S., Pasquier, D., Latorzeff, I., Supiot, S., Hennequin, C.

“…Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk…”
Get full text